

Global Pulmonary Drug Delivery Systems Market Report and Forecast 2024-2032

Market Report | 2023-10-01 | 140 pages | EMR Inc.

AVAILABLE LICENSES:

- Single User License \$2999.00
- Five User License \$3999.00
- Corporate License \$5999.00

Report description:

Global Pulmonary Drug Delivery Systems Market Report and Forecast 2024-2032

Global Pulmonary Drug Delivery Systems Market Outlook

The global pulmonary drug delivery systems market size was valued at USD 56.9 billion in 2023, driven by both technological advancements and changing healthcare needs across the globe. The market size is anticipated to grow at a CAGR of 5.6% during the forecast period of 2024-2032 to achieve a value of USD 93.3 billion by 2032.

Pulmonary Drug Delivery Systems: Introduction

Pulmonary drug delivery systems refer to methodologies and devices that administer medications directly into the lungs. The primary advantage of this mode of delivery is that it offers a direct route to the respiratory system, allowing for rapid and efficient absorption of drugs, especially those intended for local action within the lungs. Given the vast surface area and highly vascularized nature of the lungs, they serve as an excellent site for the absorption of therapeutics.

Key Trends in the Global Pulmonary Drug Delivery Systems Market

The global pulmonary drug delivery systems market is undergoing transformative changes, driven by both technological advancements, and changing healthcare needs. A significant trend is the development of smart inhalers, equipped with sensors and connectivity features, allowing for better dose tracking, patient adherence, and data collection for personalized treatment. With the rising prevalence of respiratory diseases, especially in urban areas due to pollution and changing lifestyles, there's a heightened demand for advanced and efficient inhalation devices.

Another notable shift is the exploration of the pulmonary route for the delivery of non-respiratory drugs, expanding the potential applications of these systems. The industry is also witnessing a surge in collaborations between pharmaceutical and tech companies, aiming to integrate digital technology into drug delivery for enhanced patient outcomes.

Moreover, with the global focus on reducing the invasiveness of treatments, pulmonary systems offer a promising non-invasive alternative, driving further interest and investment. In essence, the global pulmonary drug delivery systems market is on a trajectory marked by technological integration, expanded therapeutic applications, and a patient-centric approach, promising

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

improved healthcare outcomes in the respiratory domain and beyond.
Global Pulmonary Drug Delivery Systems Market Segmentation

Market Breakup by Product Type

- Dry Powder Inhalers
- Metered Dose Inhalers
- Nebulizers
- o□ Jet Nebulizers
- o□ Soft Mist Nebulizers
- o□ Ultrasonic Nebulizers
- Others

Market Breakup by Applications

- Cystic Fibrosis
- Asthma
- Allergic Rhinitis
- COPD
- Others

Market Breakup by End User

- Hospitals
- Diagnostic Centres
- Homecare Settings
- Others

Market Breakup by Region

- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa

Global Pulmonary Drug Delivery Systems Market Overview

The global pulmonary drug delivery systems market is experiencing a robust expansion, primarily driven by the escalating incidence of respiratory disorders such as asthma and COPD. As the need for effective and rapid treatment modalities grows, so does the demand for advanced inhalation devices like metered-dose inhalers, dry powder inhalers, and nebulizers. Modern technological integrations, including smart inhalers with digital adherence tracking features, are setting new standards in the industry. Beyond treating respiratory ailments, the potential of the pulmonary route for systemic drug delivery is being increasingly recognized, broadening the market's scope. Emerging markets, with their growing healthcare infrastructures and increasing awareness, are contributing significantly to the market's growth.

Furthermore, strategic collaborations between tech firms and pharmaceutical giants are fostering innovations that promise enhanced patient experiences and outcomes. Collectively, with its technological advancements, diverse therapeutic applications, and a focus on patient convenience, the global pulmonary drug delivery systems market is poised for sustained growth and evolution.

Global Pulmonary Drug Delivery Systems Market: Competitor Landscape

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

- Koninklijke Philips NV
- GlaxoSmithKline PLC
- 3M
- Boehringer Ingelheim International GmbH
- AstraZeneca
- Cipla Inc.
- Merck & Co.
- GF Health Products Inc.
- Aerogen
- PARI GmbH
- Gilbert Technologies

We at Expert Market Research always strive to provide you with the latest information. The numbers in the article are only indicative and may be different from the actual report.

Table of Contents:

- 1 Preface
 - 1.1 Objectives of the Study
 - 1.2 Key Assumptions
 - 1.3 Report Coverage - Key Segmentation and Scope
 - 1.4 Research Methodology
- 2 Executive Summary
- 3 Global Pulmonary Drug Delivery Systems Market Overview
 - 3.1 Global Pulmonary Drug Delivery Systems Market Historical Value (2017-2023)
 - 3.2 Global Pulmonary Drug Delivery Systems Market Forecast Value (2024-2032)
- 4 Global Pulmonary Drug Delivery Systems Market Landscape
 - 4.1 Global Pulmonary Drug Delivery Systems Developers Landscape
 - 4.1.1 Analysis by Year of Establishment
 - 4.1.2 Analysis by Company Size
 - 4.1.3 Analysis by Region
 - 4.2 Global Pulmonary Drug Delivery Systems Product Landscape
 - 4.2.1 Analysis by Type
 - 4.2.2 Analysis by Technology
- 5 Global Pulmonary Drug Delivery Systems Market Dynamics
 - 5.1 Market Drivers and Constraints
 - 5.2 SWOT Analysis
 - 5.3 Porter's Five Forces Model
 - 5.4 Key Demand Indicators
 - 5.5 Key Price Indicators
 - 5.6 Industry Events, Initiatives, and Trends
 - 5.7 Value Chain Analysis
- 6 Global Pulmonary Drug Delivery Systems Market Segmentation

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 6.1 Global Pulmonary Drug Delivery Systems Market by Product Type
 - 6.1.1 Market Overview
 - 6.1.2 Dry Powder Inhalers
 - 6.1.3 Metered Dose Inhalers
 - 6.1.4 Nebulizers
 - 6.1.4.1 Jet Nebulizers
 - 6.1.4.2 Soft Mist Nebulizers
 - 6.1.4.3 Ultrasonic Nebulizers
 - 6.1.5 Others
- 6.2 Global Pulmonary Drug Delivery Systems Market by Applications
 - 6.2.1 Market Overview
 - 6.2.2 Cystic Fibrosis
 - 6.2.3 Asthma
 - 6.2.4 Allergic Rhinitis
 - 6.2.5 COPD
 - 6.2.6 Others
- 6.3 Global Pulmonary Drug Delivery Systems Market by End User
 - 6.3.1 Market Overview
 - 6.3.2 Hospitals
 - 6.3.3 Diagnostic Centres
 - 6.3.4 Homecare Settings
 - 6.3.5 Others
- 6.4 Global Pulmonary Drug Delivery Systems Market by Region
 - 6.4.1 Market Overview
 - 6.4.2 North America
 - 6.4.3 Europe
 - 6.4.4 Asia Pacific
 - 6.4.5 Latin America
 - 6.4.6 Middle East and Africa
- 7 North America Pulmonary Drug Delivery Systems Market
 - 7.1 Market Share by Country
 - 7.2 United States of America
 - 7.3 Canada
- 8 Europe Pulmonary Drug Delivery Systems Market
 - 8.1 Market Share by Country
 - 8.2 United Kingdom
 - 8.3 Germany
 - 8.4 France
 - 8.5 Italy
 - 8.6 Others
- 9 Asia Pacific Pulmonary Drug Delivery Systems Market
 - 9.1 Market Share by Country
 - 9.2 China
 - 9.3 Japan
 - 9.4 India
 - 9.5 ASEAN
 - 9.6 Australia

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 9.7 Others
- 10 Latin America Pulmonary Drug Delivery Systems Market
 - 10.1 Market Share by Country
 - 10.2 Brazil
 - 10.3 Argentina
 - 10.4 Mexico
 - 10.5 Others
- 11 Middle East and Africa Pulmonary Drug Delivery Systems Market
 - 11.1 Market Share by Country
 - 11.2 Saudi Arabia
 - 11.3 United Arab Emirates
 - 11.4 Nigeria
 - 11.5 South Africa
 - 11.6 Others
- 12 Patent Analysis
 - 12.1 Analysis by Type of Patent
 - 12.2 Analysis by Publication year
 - 12.3 Analysis by Issuing Authority
 - 12.4 Analysis by Patent Age
 - 12.5 Analysis by CPC Analysis
 - 12.6 Analysis by Patent Valuation
 - 12.7 Analysis by Key Players
- 13 Grants Analysis
 - 13.1 Analysis by year
 - 13.2 Analysis by Amount Awarded
 - 13.3 Analysis by Issuing Authority
 - 13.4 Analysis by Grant Application
 - 13.5 Analysis by Funding Institute
 - 13.6 Analysis by NIH Departments
 - 13.7 Analysis by Recipient Organization
- 14 Funding Analysis
 - 14.1 Analysis by Funding Instances
 - 14.2 Analysis by Type of Funding
 - 14.3 Analysis by Funding Amount
 - 14.4 Analysis by Leading Players
 - 14.5 Analysis by Leading Investors
 - 14.6 Analysis by Geography
- 15 Partnership and Collaborations Analysis
 - 15.1 Analysis by Partnership Instances
 - 15.2 Analysis by Type of Partnership
 - 15.3 Analysis by Leading Players
 - 15.4 Analysis by Geography
- 16 Regulatory Framework
 - 16.1 Regulatory Overview
 - 16.1.1 US FDA
 - 16.1.2 EU EMA
 - 16.1.3 INDIA CDSCO

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 16.1.4 JAPAN PMDA
- 16.1.5 Others
- 17 Supplier Landscape
 - 17.1 Koninklijke Philips NV
 - 17.1.1 Financial Analysis
 - 17.1.2 Product Portfolio
 - 17.1.3 Demographic Reach and Achievements
 - 17.1.4 Mergers and Acquisition
 - 17.1.5 Certifications
 - 17.2 GlaxoSmithKline PLC
 - 17.2.1 Financial Analysis
 - 17.2.2 Product Portfolio
 - 17.2.3 Demographic Reach and Achievements
 - 17.2.4 Mergers and Acquisition
 - 17.2.5 Certifications
 - 17.3 3M
 - 17.3.1 Financial Analysis
 - 17.3.2 Product Portfolio
 - 17.3.3 Demographic Reach and Achievements
 - 17.3.4 Mergers and Acquisition
 - 17.3.5 Certifications
 - 17.4 Novartis AG
 - 17.4.1 Financial Analysis
 - 17.4.2 Product Portfolio
 - 17.4.3 Demographic Reach and Achievements
 - 17.4.4 Mergers and Acquisition
 - 17.4.5 Certifications
 - 17.5 Boehringer Ingelheim International GmbH
 - 17.5.1 Financial Analysis
 - 17.5.2 Product Portfolio
 - 17.5.3 Demographic Reach and Achievements
 - 17.5.4 Mergers and Acquisition
 - 17.5.5 Certifications
 - 17.6 AstraZeneca
 - 17.6.1 Financial Analysis
 - 17.6.2 Product Portfolio
 - 17.6.3 Demographic Reach and Achievements
 - 17.6.4 Mergers and Acquisition
 - 17.6.5 Certifications
 - 17.7 Cipla Inc.
 - 17.7.1 Financial Analysis
 - 17.7.2 Product Portfolio
 - 17.7.3 Demographic Reach and Achievements
 - 17.7.4 Mergers and Acquisition
 - 17.7.5 Certifications
 - 17.8 Merck & Co.
 - 17.8.1 Financial Analysis

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 17.8.2 Product Portfolio
- 17.8.3 Demographic Reach and Achievements
- 17.8.4 Mergers and Acquisition
- 17.8.5 Certifications
- 17.9 GF Health Products Inc.
 - 17.9.1 Financial Analysis
 - 17.9.2 Product Portfolio
 - 17.9.3 Demographic Reach and Achievements
 - 17.9.4 Mergers and Acquisition
 - 17.9.5 Certifications
- 17.10 Aerogen
 - 17.10.1 Financial Analysis
 - 17.10.2 Product Portfolio
 - 17.10.3 Demographic Reach and Achievements
 - 17.10.4 Mergers and Acquisition
 - 17.10.5 Certifications
- 17.11 PARI GmbH
 - 17.11.1 Financial Analysis
 - 17.11.2 Product Portfolio
 - 17.11.3 Demographic Reach and Achievements
 - 17.11.4 Mergers and Acquisition
 - 17.11.5 Certifications
- 17.12 Gilbert Technologies
 - 17.12.1 Financial Analysis
 - 17.12.2 Product Portfolio
 - 17.12.3 Demographic Reach and Achievements
 - 17.12.4 Mergers and Acquisition
 - 17.12.5 Certifications
- 18 Global Pulmonary Drug Delivery Systems Market - Distribution Model (Additional Insight)
 - 18.1 Overview
 - 18.2 Potential Distributors
 - 18.3 Key Parameters for Distribution Partner Assessment
- 19 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 20 Company Competitiveness Analysis (Additional Insight)
 - 20.1 Very Small Companies
 - 20.2 Small Companies
 - 20.3 Mid-Sized Companies
 - 20.4 Large Companies
 - 20.5 Very Large Companies
- 21 Payment Methods (Additional Insight)
 - 21.1 Government Funded
 - 21.2 Private Insurance
 - 21.3 Out-of-Pocket

*Additional insights provided are customisable as per client requirements.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Global Pulmonary Drug Delivery Systems Market Report and Forecast 2024-2032

Market Report | 2023-10-01 | 140 pages | EMR Inc.

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scott's-international.com

ORDER FORM:

Select license	License	Price
	Single User License	\$2999.00
	Five User License	\$3999.00
	Corporate License	\$5999.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scott's-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2026-03-16"/>
		Signature	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scott's-international.com

www.scott's-international.com